Nexavar starts Phase III adjuvant trial in liver cancer
This article was originally published in Scrip
Bayerand Onyx have commenced a Phase III trial evaluating their multi-targeted anticancer Nexavar (sorafenib) as an adjuvant treatment in hepatocellular carcinoma (HCC), or primary liver cancer. The US FDAhas completed a special protocol assessment (SPA) for the STORM (Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma) trial, which is expected to enrol about 1,100 patients who had their tumours removed. The study will be conducted at more than 200 sites in North America, South America, Europe and the Asia-Pacific region.